Results 81 to 90 of about 1,157 (167)

Anti-M antibodies: Biphasic (reactive at room temperature and at 37°C): A case series

open access: yesAsian Journal of Transfusion Science, 2016
Anti-M antibody, which is not reactive at 37°C, is not clinically significant. Reports of clinically significant anti-M antibodies causing hemolytic disease of the fetus and the newborn (HDFN) and delayed hemolytic transfusion reaction (DHTR) are ...
Siddhi P Shah   +3 more
doaj   +1 more source

Hemolytic disease of the fetus and newborn caused by anti‐s(D) antibody in a GP.Mur/Mur Thai mother and review of the prevalence of s(D) in Thai blood donors

open access: yes, 2022
BACKGROUND: Low‐prevalence antigen s(D) (MNS23) is encoded by GYPB c.173C > G. Hemolytic disease of the fetus and newborn (HDFN) due to anti‐s(D) is rare. A mother delivered a newborn whose red blood cells (RBCs) were DAT‐positive and was later diagnosed
Lopez, Genghis H.   +10 more
core   +1 more source

Anti-D-induced severe hemolytic disease of the newborn in an Omani newborn born a rhesus-positive mother

open access: yes, 2018
Hemolytic disease of the fetus and newborn (HDFN) due to anti-D antibodies is a well-known complication of rhesus (Rh) incompatibility, encountered in D-positive babies born to alloimmunized D-negative mothers who have been sensitized during previous ...
Hanan F. Nazir   +5 more
core   +1 more source

Severe cholestasis in neonates with hemolytic disease of the fetus and newborn - a case report

open access: yes
Hemolytic disease of the fetus and newborn (HDFN) may cause severe cholestasis with direct bilirubin concentrations reaching up to 50 times the upper limit of normal.
Natalia Mazanowska   +9 more
core   +1 more source

Identification of red blood cell antibodies in maternal breast milk implicated in prolonged hemolytic disease of the fetus and newborn.

open access: yes, 2019
© 2019 AABB BACKGROUND: Alloantibodies against more than 50 non-ABO blood group antigens have been implicated in hemolytic disease of the fetus and newborn (HDFN) and are expected to wane within weeks after delivery.
Y. Delores Mo   +18 more
core   +1 more source

Confusing Blood Group Antibodies in Obstetrics: Focus on the Risk of Hemolytic Disease of the Fetus and Newborn.

open access: yes
During routine prenatal antibody screening, maternal reactivity is sometimes detected for which the clinical significance is unclear. As a result, the strategy for monitoring these antibodies during pregnancy, to mitigate the risk of hemolytic disease of
Blackall, Douglas, Tomlinson, Mark W
core   +1 more source

Maternal IgG in hemolytic disease of the fetus and newborn-ABO incompatibility

open access: yes
BACKGROUND Hemolytic disease of the fetus and newborn (HDFN) is a type of anemia in the fetus or newborn, characterized by anemia, jaundice, hyperbilirubinemia, and brain damage. IgG is the only antibody that can cross the placenta. The IgG subtypes have
Wibowo, Heri   +2 more
core   +1 more source

“Block D” Phenomenon in Hemolytic Disease of Fetus and Newborn: The Immunohematological Implications

open access: yesGlobal Journal of Transfusion Medicine
Background and Objectives: “Block D” in hemolytic disease of the fetus and newborn (HDFN) is quite rare and should be evaluated meticulously. We analyzed “Block D” phenomenon in neonates with HDFN due to rhesus (Rh) incompatibilities.
Sourav Mukherjee   +2 more
doaj   +1 more source

Case Series: 11 Cases of Hemolytic Disease of The Fetus And Newborn Due to Kell Blood Group Incompatibility

open access: yes
Hemolytic disease of the fetus and newborn (HDFN) results from the destruction of the newborn's red blood cells or the fetus by the mother's immune globulin G antibodies.
Aycan, Nur   +4 more
core   +1 more source

Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn [PDF]

open access: yes
ObjectiveNipocalimab is a neonatal fragment crystallizable (Fc) receptor (FcRn)—blocking monoclonal antibody that inhibits placental immunoglobulin G (IgG) transfer and lowers circulating maternal IgG levels.
Lam, E.   +43 more
core   +1 more source

Home - About - Disclaimer - Privacy